Colinz Laboratories (531210.BO) Stock Price

Colinz Laboratories Price

CLOSED
73.50
​
Market closed

Revenue at Colinz Laboratories has contracted by 0.1% per year over the past 13 years to 65.28 M INR. Earnings per share have grown at 17.6% per year over the last 13 years. Colinz Laboratories's net margin stands at 7.6%, up from 3.4% several years earlier.

Colinz Laboratories stock price

Access this data via the Eulerpool API

Colinz Laboratories business model & stock analysis

Colinz Laboratories Ltd. engages in the manufacture of pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, injectable, ointments, and creams. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2004-01-13. The firm is engaged in the manufacturing and marketing various allopathic and ayurvedic pharmaceutical formulations in the dosage forms of tablets, capsules, liquid orals and ointments, among others. The company provides physicians with products in the treatment of hypertension, cholesterol, diabetes, piles, pyrexia and malaria. The company provides gynecologists with specialized products in the treatments of morning sickness, infertility, intrauterine growth restriction (IUGR) and maintenance of pregnancy. The company also offers other products, such as hematinic, antispasmodics, anti-inflammatory/anti-allergic tablets, capsules gel and medicated shampoo. The firm markets its products in the states of Maharashtra, Karnataka, Andhra Pradesh, Gujarat, Rajasthan, Madhya Pradesh, Chhattisgarh and West Bengal through its own marketing staff.

Frequently asked questions about Colinz Laboratories

Converted at the current exchange rate, the Colinz Laboratories share trades at 0.68 EUR (73.50 INR).

The revenue cannot currently be calculated for Colinz Laboratories.

The profit cannot currently be calculated for Colinz Laboratories.

The P/E ratio cannot be calculated for Colinz Laboratories at the moment.

The P/S cannot be calculated for Colinz Laboratories currently.

The Eulerpool Quality Score for Colinz Laboratories is 4/10.

The ISIN of Colinz Laboratories is INE923C01011. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Colinz Laboratories is 531210.BO. The ticker symbol is used to trade Colinz Laboratories shares on the stock exchange.

Fair ValueTerminal
75.71 INR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website colinz.com
Country
Currency
INR
Initial public offering
Jan 13, 2004
ISIN
INE923C01011
Cusip
Y1674A111
Market capitalization
185.22 M INRMicro Cap
52-Week Range
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
37.41
P/B Ratio
1.95
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
4.91 %
Gross Margin
67.98 %
EBIT Margin
5.57 %
Net Margin
7.61 %
EPS (Earnings Per Share)
1.97 INR
Net Debt / EBIT
-13.49
Debt/Equity
0.07
Last updated Oct 5, 2026, 12:57 PM

Colinz Laboratories Peer Group

Colinz Laboratories FIGI

CLZ:IN · BBG000BGWY38CLZ:IB · BBG000BGWYF5